Senju Pharmaceutical Highlighted Study Results of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration
Shots:
- The study published in Ophthalmology and Therapy evaluating ranibizumab biosimilar (RBZ BS) in patients with nAMD
- The results showed that ranibizumab biosimilar was found to be the most cost-effective when used in treat-and-extend (TAE) regimens and pro re nata (PRN) regimens and best societal care (BSC) compared to other anti-VEGF treatments, acc. to a recent Japanese study
- The magnitude of difference in 2yr. treatment frequencies b/w (RBZ BS) TAE and AFL TAE in the indirect comparison study was 5.9 times higher which was larger than the predicted outcome from real-world practice as suggested by retrospective observational studies conducted in Japan and other foreign settings
Ref: Centerforbiosimilar | Image: Senju Pharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
